255 related articles for article (PubMed ID: 26362335)
1. Prediction of disability progression in fingolimod-treated patients.
Lattanzi S; Danni M; Cerqua R; Taffi R; Provinciali L; Silvestrini M
J Neurol Sci; 2015 Nov; 358(1-2):432-4. PubMed ID: 26362335
[TBL] [Abstract][Full Text] [Related]
2. Long-term results from a phase 2 extension study of fingolimod at high and approved dose in relapsing multiple sclerosis.
Montalban X; Comi G; Antel J; O'Connor P; de Vera A; Cremer M; Sfikas N; von Rosenstiel P; Kappos L
J Neurol; 2015 Dec; 262(12):2627-34. PubMed ID: 26338810
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of fingolimod in patients with highly active relapsing-remitting multiple sclerosis.
Derfuss T; Bergvall NK; Sfikas N; Tomic DL
Curr Med Res Opin; 2015; 31(9):1687-91. PubMed ID: 26121423
[TBL] [Abstract][Full Text] [Related]
4. Effects of Three Months Fingolimod Therapy on Heart Rate.
Simula S; Laitinen T; Laitinen TM; Tarkiainen T; Hartikainen JE; Hartikainen P
J Neuroimmune Pharmacol; 2015 Dec; 10(4):651-4. PubMed ID: 26092537
[TBL] [Abstract][Full Text] [Related]
5. Oral therapies for treatment of relapsing-remitting multiple sclerosis in Austria: a 2-year comparison using an inverse probability weighting method.
Guger M; Enzinger C; Leutmezer F; Kraus J; Kalcher S; Kvas E; Berger T;
J Neurol; 2020 Jul; 267(7):2090-2100. PubMed ID: 32246251
[TBL] [Abstract][Full Text] [Related]
6. Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England.
Maruszczak MJ; Montgomery SM; Griffiths MJ; Bergvall N; Adlard N
J Med Econ; 2015; 18(11):874-85. PubMed ID: 26055952
[TBL] [Abstract][Full Text] [Related]
7. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study.
Devonshire V; Havrdova E; Radue EW; O'Connor P; Zhang-Auberson L; Agoropoulou C; Häring DA; Francis G; Kappos L;
Lancet Neurol; 2012 May; 11(5):420-8. PubMed ID: 22494956
[TBL] [Abstract][Full Text] [Related]
8. Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimod.
Ziemssen T; Kern R; Cornelissen C
BMC Neurol; 2016 Aug; 16():129. PubMed ID: 27502119
[TBL] [Abstract][Full Text] [Related]
9. Half-dose fingolimod for treating relapsing-remitting multiple sclerosis: Observational study.
Zecca C; Merlini A; Disanto G; Rodegher M; Panicari L; Romeo MAL; Candrian U; Messina MJ; Pravatà E; Moiola L; Stefanin C; Ghezzi A; Perrone P; Patti F; Comi G; Gobbi C; Martinelli V
Mult Scler; 2018 Feb; 24(2):167-174. PubMed ID: 28273776
[TBL] [Abstract][Full Text] [Related]
10. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.
Kalincik T; Horakova D; Spelman T; Jokubaitis V; Trojano M; Lugaresi A; Izquierdo G; Rozsa C; Grammond P; Alroughani R; Duquette P; Girard M; Pucci E; Lechner-Scott J; Slee M; Fernandez-Bolanos R; Grand'Maison F; Hupperts R; Verheul F; Hodgkinson S; Oreja-Guevara C; Spitaleri D; Barnett M; Terzi M; Bergamaschi R; McCombe P; Sanchez-Menoyo J; Simo M; Csepany T; Rum G; Boz C; Havrdova E; Butzkueven H;
Ann Neurol; 2015 Mar; 77(3):425-35. PubMed ID: 25546031
[TBL] [Abstract][Full Text] [Related]
11. Five-year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis.
Izquierdo G; O'Connor P; Montalban X; von Rosenstiel P; Cremer M; de Vera A; Sfikas N; Francis G; Radue EW; Kappos L
Mult Scler; 2014 Jun; 20(7):877-81. PubMed ID: 24293455
[TBL] [Abstract][Full Text] [Related]
12. The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis.
Warrender-Sparkes M; Spelman T; Izquierdo G; Trojano M; Lugaresi A; Grand'Maison F; Havrdova E; Horakova D; Boz C; Oreja-Guevara C; Alroughani R; Iuliano G; Duquette P; Girard M; Terzi M; Hupperts R; Grammond P; Petersen T; Fernandez-Bolaños R; Fiol M; Pucci E; Lechner-Scott J; Verheul F; Cristiano E; Van Pesch V; Petkovska-Boskova T; Moore F; Kister I; Bergamaschi R; Saladino ML; Slee M; Barnett M; Amato MP; Shaw C; Shuey N; Young C; Gray O; Kappos L; Butzkueven H; Kalincik T; Jokubaitis V;
Mult Scler; 2016 Apr; 22(4):520-32. PubMed ID: 26199347
[TBL] [Abstract][Full Text] [Related]
13. Assessing 'No Evidence of Disease Activity' Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice: A Retrospective Analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) Study.
Weinstock-Guttman B; Medin J; Khan N; Korn JR; Lathi E; Silversteen J; Calkwood J; Silva D; Zivadinov R;
CNS Drugs; 2018 Jan; 32(1):75-84. PubMed ID: 29270772
[TBL] [Abstract][Full Text] [Related]
14. Lateral switch to IFN beta-1a 44 mcg may be effective as escalation switch to fingolimod in selected persons with relapsing remitting multiple sclerosis: a real-world setting experience.
D'Amico E; Patti F; Zanghì A; Lo Fermo S; Chisari CG; Zappia M
Expert Rev Clin Pharmacol; 2018 May; 11(5):531-536. PubMed ID: 29521113
[TBL] [Abstract][Full Text] [Related]
15. No impact of current therapeutic strategies on disease reactivation after natalizumab discontinuation: a comparative analysis of different approaches during the first year of natalizumab discontinuation.
Capobianco M; di Sapio A; Malentacchi M; Malucchi S; Matta M; Sperli F; Bertolotto A
Eur J Neurol; 2015 Mar; 22(3):585-7. PubMed ID: 24995482
[TBL] [Abstract][Full Text] [Related]
16. Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod.
Fragoso YD; Spelman T; Boz C; Alroughani R; Lugaresi A; Vucic S; Butzkueven H; Terzi M; Havrdova E; Horakova D; Granella F; Olascoaga J; Sánchez-Menoyo JL; Pucci E; Barnett M; Brooks JBB; Haartsen J;
Mult Scler Relat Disord; 2018 Jan; 19():105-108. PubMed ID: 29182993
[TBL] [Abstract][Full Text] [Related]
17. Real-life long-term effectiveness of fingolimod in Swiss patients with relapsing-remitting multiple sclerosis.
Zecca C; Roth S; Findling O; Perriard G; Bachmann V; Pless ML; Baumann A; Kamm CP; Lalive PH; Czaplinski A
Eur J Neurol; 2018 May; 25(5):762-767. PubMed ID: 29431876
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy and safety of fingolimod in routine clinical practice in patients with relapsing-remitting multiple sclerosis in Spain: an intermediate analysis of the MS NEXT study].
Mallada-Frechin J; Meca-Lallana V; Barrero F; Martinez-Gines ML; Marzo-Sola ME; Ricart J; Garcia E; En Representacion de Los Investigadores Del Estudio Ms Next ERLIDEMN
Rev Neurol; 2018 Sep; 67(5):157-167. PubMed ID: 30047118
[TBL] [Abstract][Full Text] [Related]
19. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
Kappos L; Radue EW; O'Connor P; Polman C; Hohlfeld R; Calabresi P; Selmaj K; Agoropoulou C; Leyk M; Zhang-Auberson L; Burtin P;
N Engl J Med; 2010 Feb; 362(5):387-401. PubMed ID: 20089952
[TBL] [Abstract][Full Text] [Related]
20. Baseline Differences in Minor Lymphocyte Subpopulations may Predict Response to Fingolimod in Relapsing-Remitting Multiple Sclerosis Patients.
Teniente-Serra A; Hervás JV; Quirant-Sánchez B; Mansilla MJ; Grau-López L; Ramo-Tello C; Martínez-Cáceres EM
CNS Neurosci Ther; 2016 Jul; 22(7):584-92. PubMed ID: 27080413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]